NeXine™ is the next generation of long-acting cytokine technology platform developed by Longbio. The platform is based on the co-founder, Dr. Sun’s fc-fusion protein technology, and multiple candidate cytokine drug molecules have been developed based on this platform. The long-acting G-CSF (Benegrastim) has been approved by US FDA and China NMPA.

Dosing interval of Long acting cytokine that developed by NeXine™ platform